Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis
2007564 citationsShanu F. Roemer, Joseph E. Parisi et al.Brainprofile →
Citations per year, relative to S J Pittock S J Pittock (= 1×)
peers
Ching‐Piao Tsai
Countries citing papers authored by S J Pittock
Since
Specialization
Citations
This map shows the geographic impact of S J Pittock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S J Pittock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S J Pittock more than expected).
This network shows the impact of papers produced by S J Pittock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S J Pittock. The network helps show where S J Pittock may publish in the future.
Co-authorship network of co-authors of S J Pittock
This figure shows the co-authorship network connecting the top 25 collaborators of S J Pittock.
A scholar is included among the top collaborators of S J Pittock based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with S J Pittock. S J Pittock is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Levy, Miles, Achim Berthele, Ichiro Nakashima, et al.. (2020). Efficacy and safety of eculizumab in patients with neuromyelitis optica spectrum disorder previously treated with rituximab: findings from PREVENT. Multiple Sclerosis Journal. 26. 1–1.4 indexed citations
4.
Oreja‐Guevara, Celia, Jacqueline Palace, S J Pittock, et al.. (2020). Regional outcomes of eculizumab treatment in patients with aquaporin-4 immunoglobin G-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study. European Journal of Neurology. 27. 90–90.1 indexed citations
5.
Berthele, Achim, Celia Oreja‐Guevara, Jacqueline Palace, et al.. (2020). Pharmacokinetic/pharmacodynamic properties of eculizumab support established efficacy in patients with NMOSD: findings from the phase 3 PREVENT study. European Journal of Neurology. 27. 351–351.3 indexed citations
6.
Wingerchuk, Dean M., S J Pittock, Achim Berthele, et al.. (2020). Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder. mediaTUM (Technical University of Munich). 94.1 indexed citations
7.
Berthele, Achim, S J Pittock, Miles Levy, et al.. (2019). Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the PREVENT study. Multiple Sclerosis Journal. 25. 294–295.2 indexed citations
8.
Palace, Jacqueline, S J Pittock, Achim Berthele, et al.. (2019). Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: phase 3 PREVENT study. Multiple Sclerosis Journal. 25. 737–738.1 indexed citations
9.
Wingerchuk, Dean M., S J Pittock, Achim Berthele, et al.. (2019). Long-term Safety And Effectiveness Of Eculizumab In Neuromyelitis Optica Spectrum Disorder. Multiple Sclerosis Journal. 25. 107–107.2 indexed citations
Chan, KH, et al.. (2008). Coexisting Autoimmune Channelopathies: Neuromyelitis Optica (NMO) With Myasthenia Gravis (MG).1 indexed citations
12.
Roemer, Shanu F., Joseph E. Parisi, Vanda A. Lennon, et al.. (2007). Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 130(5). 1194–1205.564 indexed citations breakdown →
13.
Wingerchuk, Dean M., Vanda A. Lennon, S J Pittock, Claudia F. Lucchinetti, & B. G. Weinshenker. (2006). Revised diagnostic criteria for neuromyelitis optica. American Journal of Ophthalmology. 142(4). 715–716.93 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.